Becton, Dickinson and Company Announces Publication of an Independent Analysis of Drug-Coated Balloon Safety Data for Femoropopliteal Peripheral Arterial Disease
October 28, 2019
October 28, 2019
FRANKLIN LAKES, New Jersey, Oct. 28 -- Becton, Dickinson and Co., a medical technology company, issued the following news release:
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a company-initiated, independent analysis of the LUTONIX(R) 035 Drug Coated Balloon (DCB) femoropopliteal clinical program in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions. These data wer . . .
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a company-initiated, independent analysis of the LUTONIX(R) 035 Drug Coated Balloon (DCB) femoropopliteal clinical program in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions. These data wer . . .